Onto Innovation (ONTO) Q4 2025 earnings review
Record Revenue, Messy Margins
Onto delivered a sharp operational recovery, breaking the Q3 trough with a 22% sequential revenue jump to a record $267M. However, the GAAP P&L is noisy: Net Income collapsed 79% YoY ($10.5M vs $48.8M) due to massive restructuring charges and M&A costs tied to the Semilab acquisition. While Non-GAAP Gross Margins held steady at 54.6%, the GAAP figure plunged to 46.4%. Guidance for 26Q1 is robust, forecasting continued acceleration to ~$280M revenue, suggesting the growth engine (AI/HBM) is fully engaged despite the accounting noise.
🐂 Bull Case
Revenue surged 22% sequentially from the Q3 'low watermark,' driven by AI packaging and the Semilab acquisition. 26Q1 guidance ($275-285M) implies the momentum continues, firmly putting the Q3 dip in the rearview mirror.
Management cited a 'robust upcycle' fueled by global AI investment. The closing of a $240M volume purchase agreement for Dragonfly systems confirms strong visibility through 2027.
🐻 Bear Case
GAAP financials were crushed by 'Restructuring and other' costs—specifically a massive ~$21.8M hit to Cost of Revenue. While Non-GAAP looks clean, such large adjustments in COGS raise questions about inventory write-downs or integration frictions.
Despite record revenue, profitability has degraded. Non-GAAP EPS fell 17% YoY ($1.26 vs $1.51) and Non-GAAP Operating Margin compressed significantly to 25.2% from 28.6% a year ago.
⚖️ Verdict: 🟢
Bullish. The operational turnaround is undeniable with record revenues and strong forward guidance. The GAAP margin noise is ugly but appears to be one-time integration pain from the Semilab deal. The core thesis—AI/HBM driven growth—is intact.
Key Themes
AI & Advanced Packaging Acceleration
The narrative has shifted from 'Q3 pause' to 'Q4 acceleration.' A new $240M volume purchase agreement for Dragonfly systems (2D inspection/3D metrology) supporting HBM expansion through 2027 validates the longevity of the AI capex cycle.
The Gap in GAAP Margins
A massive divergence appeared this quarter. GAAP Gross Margin fell to 46.4% while Non-GAAP stayed at 54.6%. The bridge is a $21.8M 'restructuring' charge sitting directly in Cost of Goods Sold. Investors need clarity on whether this is scrapped inventory or one-off M&A integration costs.
Semilab Acquisition Closed
The acquisition is complete and integrated into the financials. Management explicitly linked the Q4 revenue record and future growth confidence to the 'deep and broad portfolio' including these new assets. The quick integration likely contributed to the noisy GAAP numbers but sets the stage for 2026 outperformance.
Inventory Build continues
Inventory levels remain elevated at $298M, up from $286M a year ago. However, given the strong forward guidance and the $240M HBM agreement, this looks more like strategic buffering for a 2026 ramp rather than a liability.
Other KPIs
Decreased significantly from $852M in 2024Q4 and $983M in 25Q3. This drop reflects the cash outlay for the Semilab acquisition. Balance sheet remains healthy but is now more leveraged towards operational execution than cash hoarding.
Strong generation despite the net income drop, indicating that the GAAP earnings hit was largely non-cash (depreciation/amortization/write-downs). Represents ~35% of revenue, a healthy conversion rate.
Onto officially crossed the $1B annual revenue mark (+1.8% YoY). While growth was modest due to the mid-year dip, the Q4 exit velocity suggests FY26 will see much higher growth rates.
Guidance
Accelerating. The midpoint ($280M) implies ~5% sequential growth off a record Q4, and ~5% YoY growth. This confirms the 'upcycle' narrative.
Accelerating. Midpoint ($1.31) is up sequentially from Q4's $1.26, though still trailing the peak profitability of early FY25 ($1.51). Margins are recovering slower than revenue.
Stable/Rising. The midpoint (55.1%) suggests an improvement from Q4's 54.6%. Management is successfully passing on costs or improving mix despite the integration efforts.
Key Questions
COGS Restructuring Specifics
Can you detail the $21.8M restructuring charge within Cost of Revenue? Is this a write-down of legacy inventory following the Semilab acquisition, or purely integration costs?
Semilab Contribution
How much of the Q4 revenue beat ($267M vs $260M guide high) came from the partial quarter contribution of Semilab assets versus organic core business growth?
Margin Recovery Pace
Non-GAAP Operating Margins are guided to ~26% for Q1, still below the ~29% seen a year ago. When do you expect to return to peak operating leverage?